Oncternal pre-announces $34.3M cash; 20:1 reverse stock split effective Jan 8

Oncternal Therapeutics, Inc.

Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2023; subject to closing procedures.
Shares outstanding: ~59.2M pre-split; ~3.0M post-split after 20:1 reverse stock split.
Reverse stock split effective 12:01 a.m. ET on Jan 8, 2024; new CUSIP 68236P206.
No fractional shares issued; fractional holders receive proportional cash payment.
Exercise prices and share counts for stock options and warrants adjusted proportionally.

item 2.02 item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Oncternal Therapeutics, Inc. reported preliminary financial results for as of December 31, 2023.

Period: as of December 31, 2023
Result: preliminary results

Exact text from the filing

Oncternal Therapeutics, Inc. (“Oncternal”) estimates that, as of December 31, 2023, its cash and cash equivalents were $34.3 million and it had 59.2 million shares of common stock, par value $0.001 per share (“Common Stock”) outstanding, or 3.0 million shares of Common Stock after giving effect to the Reverse Stock Split (defined below). These amounts are preliminary and are subject to completion of financial closing procedures.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Oncternal Therapeutics, Inc.: Amended restated certificate of incorporation to effect a 1-for-20 reverse stock split (effective 2024-01-08).

Change: charter amendment
Effective: 2024-01-08

Exact text from the filing

On January 3, 2024, Oncternal filed an amendment (the “Amendment”) to its restated certificate of incorporation to effectuate a reverse stock split of Oncternal’s Common Stock.

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-002434

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.